Targeting p21-activated kinase 4 (PAK4) with pyrazolo[3,4-d]pyrimidine derivative SPA7012 attenuates hepatic ischaemia-reperfusion injury in mice

Yuancheng Maoa Department of Biochemistry and Research Institute for Endocrine Sciences, Jeonbuk National University Medical School, Jeonju, Republic of KoreaView further author information

Eun Leeb Research Institute of Pharmaceutical Sciences, College of Pharmacy, Sookmyung Women's University, Seoul, Republic of KoreaView further author information

Xiaohui Yangc School of Pharmacy, Jeonbuk National University, Jeonju, Republic of KoreaView further author information

Eun Ju Baec School of Pharmacy, Jeonbuk National University, Jeonju, Republic of KoreaCorrespondence[email protected]
View further author information

Raok Jeonb Research Institute of Pharmaceutical Sciences, College of Pharmacy, Sookmyung Women's University, Seoul, Republic of KoreaCorrespondence[email protected]
View further author information

Byung-Hyun Parka Department of Biochemistry and Research Institute for Endocrine Sciences, Jeonbuk National University Medical School, Jeonju, Republic of KoreaCorrespondence[email protected]
View further author information

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Targeting p21-activated kinase 4 (PAK4) with pyrazolo[3,4-d]pyrimidine derivative SPA7012 attenuates hepatic ischaemia-reperfusion injury in mice

Articles from other publishers (2)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Targeting p21-activated kinase 4 (PAK4) with pyrazolo[3,4-d]pyrimidine derivative SPA7012 attenuates hepatic ischaemia-reperfusion injury in mice

Citations (2)

Articles from other publishers (2)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date